Drug intelligence / Profile preview

SPEACT-2

Development stage: Preclinical
Lead developer: Sunstate Biosciences
Modality: Small Molecules, Recombinant Proteins and Enzymes

Overview

SPEACT-2 is a preclinical-stage therapeutic candidate developed by Sunstate Biosciences for the treatment of various cancers, including those characterized by low FcRn expression or KRAS mutations. The drug utilizes the company's proprietary Single Protein Encapsulation (SPE) technology, which involves a small molecule RNA polymerase inhibitor encapsulated within a protein shell. This platform is designed to leverage FcRn-associated tumor targeting to enhance the delivery and efficacy of the payload while potentially reducing systemic toxicity. The program is currently undergoing preclinical studies to generate data required for an Investigational New Drug (IND) application.

Other names: SPEACT-2SPEACT2SPEACT 2

Targets

RNAP (Bacterial dna-dependent RNA polymerase)

Beyond the preview

Go deeper on SPEACT-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPEACT-2.

Explore the full profile